Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.

CONTEXT Hemoglobin-based blood substitutes (HBBSs) are infusible oxygen-carrying liquids that have long shelf lives, have no need for refrigeration or cross-matching, and are ideal for treating hemorrhagic shock in remote settings. Some trials of HBBSs during the last decade have reported increased risks without clinical benefit. OBJECTIVE To assess the safety of HBBSs in surgical, stroke, and trauma patients. DATA SOURCES PubMed, EMBASE, and Cochrane Library searches for articles using hemoglobin and blood substitutes from 1980 through March 25, 2008; reviews of Food and Drug Administration (FDA) advisory committee meeting materials; and Internet searches for company press releases. STUDY SELECTION Randomized controlled trials including patients aged 19 years and older receiving HBBSs therapeutically. The database searches yielded 70 trials of which 13 met these criteria; in addition, data from 2 other trials were reported in 2 press releases, and additional data were included in 1 relevant FDA review. DATA EXTRACTION Data on death and myocardial infarction (MI) as outcome variables. RESULTS Sixteen trials involving 5 different products and 3711 patients in varied patient populations were identified. A test for heterogeneity of the results of these trials was not significant for either mortality or MI (for both, I2 = 0%, P > or = .60), and data were combined using a fixed-effects model. Overall, there was a statistically significant increase in the risk of death (164 deaths in the HBBS-treated groups and 123 deaths in the control groups; relative risk [RR], 1.30; 95% confidence interval [CI], 1.05-1.61) and risk of MI (59 MIs in the HBBS-treated groups and 16 MIs in the control groups; RR, 2.71; 95% CI, 1.67-4.40) with these HBBSs. Subgroup analysis of these trials indicated the increased risk was not restricted to a particular HBBS or clinical indication. CONCLUSION Based on the available data, use of HBBSs is associated with a significantly increased risk of death and MI.

[1]  W. G. Cochran.  Some Methods for Strengthening the Common χ 2 Tests , 1954 .

[2]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[3]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[4]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[5]  D. Faller,et al.  Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. , 1995, The Journal of clinical investigation.

[6]  W. Buzello,et al.  Effects of a Hemoglobin-Based Oxygen Carrier (HBOC-201) on Hemodynamics and Oxygen Transport in Patients Undergoing Preoperative Hemodilution for Elective Abdominal Aortic Surgery , 1996, Anesthesia and analgesia.

[7]  E. Orringer,et al.  A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[8]  W. Buzello,et al.  The Effects of Increased Doses of Bovine Hemoglobin on Hemodynamics and Oxygen Transport in Patients Undergoing Preoperative Hemodilution for Elective Abdominal Aortic Surgery , 1998, Anesthesia and analgesia.

[9]  M. Burmeister,et al.  Transcranial Doppler Sonography Mean Flow Velocity During Infusion of Ultrapurified Bovine Hemoglobin , 1998, Journal of neurosurgical anesthesiology.

[10]  K. Vandegriff,et al.  Arterial Blood Pressure Responses to Cell-free Hemoglobin Solutions and the Reaction with Nitric Oxide* , 1998, The Journal of Biological Chemistry.

[11]  E. Moore,et al.  The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. , 1998, Journal of the American College of Surgeons.

[12]  M. Kaste,et al.  Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. , 1999, Stroke.

[13]  A. Alayash,et al.  Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. , 1999, Journal of applied physiology.

[14]  J. D. Harviel,et al.  A Safety Assessment of Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Hemorrhagic, Hypovolemic Shock , 1999, Prehospital and Disaster Medicine.

[15]  J. Wildsmith,et al.  Haemodynamic effects of diaspirin crosslinked haemoglobin (DCLHb) given before abdominal aortic aneurysm surgery. , 1999, British journal of anaesthesia.

[16]  G. LaMuraglia,et al.  The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. , 2000, Journal of vascular surgery.

[17]  M. Goldman.  Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial , 2000 .

[18]  J. Berridge,et al.  Randomized Trial of Diaspirin Cross-linked Hemoglobin Solution as an Alternative to Blood Transfusion after Cardiac Surgery , 2000, Anesthesiology.

[19]  R. Macdonald,et al.  Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide. , 2001, Biochemical and biophysical research communications.

[20]  Irwin Gratz,et al.  Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. , 2002, The Journal of thoracic and cardiovascular surgery.

[21]  R. Koehler,et al.  Vascular response to infusions of a nonextravasating hemoglobin polymer. , 2002, Journal of applied physiology.

[22]  S. Hill,et al.  Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. , 2002, Journal of cardiothoracic and vascular anesthesia.

[23]  E. Moore,et al.  The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. , 2002, Journal of the American College of Surgeons.

[24]  J. Wahr,et al.  The Use of Bovine Hemoglobin Glutamer-250 (Hemopure®) in Surgical Patients: Results of a Multicenter, Randomized, Single-Blinded Trial , 2002, Anesthesia and analgesia.

[25]  E. Mascha,et al.  EFFECT OF DIASPIRIN CROSSLINKED HEMOGLOBIN (DCLHb HemAssist™) DURING HIGH BLOOD LOSS SURGERY ON SELECTED INDICES OF ORGAN FUNCTION * , 2002, Artificial cells, blood substitutes, and immobilization biotechnology.

[26]  E. Mascha,et al.  Diaspirin-Crosslinked Hemoglobin Reduces Blood Transfusion in Noncardiac Surgery: A Multicenter, Randomized, Controlled, Double-Blinded Trial , 2003, Anesthesia and analgesia.

[27]  A. Malavalli,et al.  MP4, a new nonvasoactive PEG‐Hb conjugate , 2003, Transfusion.

[28]  B. Riou,et al.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" Multicenter Study , 2003, Intensive Care Medicine.

[29]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[30]  E. Bloomfield,et al.  A prospective trial of diaspirin cross-linked hemoglobin solution in patients after elective repair of abdominal aortic aneurysm. , 2004, Military medicine.

[31]  A. Greenburg,et al.  Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. , 2004, Journal of the American College of Surgeons.

[32]  M. Gladwin,et al.  Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. , 2005, The Journal of clinical investigation.

[33]  A. Butch,et al.  Lactate Measurement Interference by Hemoglobin-Based Oxygen Carriers (Oxyglobin®, Hemopure®, and Hemolink™) , 2005, Anesthesia and analgesia.

[34]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[35]  B. Manjula,et al.  Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. , 2006, Blood.

[36]  Blood-substitute study is criticized by U.S. agency. , 2006, Wall Street journal.

[37]  P. Lurie,et al.  Sometimes the Silence Can Be Like the Thunder: Access to Pharmaceutical Data at the Fda , 2006 .

[38]  R. Winslow,et al.  A Multicenter Clinical Study of the Safety and Activity of Maleimide-Polyethylene Glycol–modified Hemoglobin (Hemospan®) in Patients Undergoing Major Orthopedic Surgery , 2006, Anesthesiology.

[39]  K. Lowe.  Blood substitutes: from chemistry to clinic , 2006 .

[40]  D. Fergusson,et al.  The future of clinical trials evaluating blood substitutes. , 2008, JAMA.

[41]  Incomplete financial disclosure in a study of cell-free hemoglobin-based blood substitutes and risks of myocardial infarction and death. , 2008, JAMA.

[42]  Hemoglobin-based blood substitutes and risk of myocardial infarction and death. , 2008 .